119 related articles for article (PubMed ID: 37247200)
1. Longitudinal change of circulating tumor cell level and its relationship with immune checkpoint inhibitor-based treatment benefits in unresectable, metastatic colorectal cancer patients.
Fan H; Bai L; Bai K
Scand J Clin Lab Invest; 2023 Jul; 83(4):227-233. PubMed ID: 37247200
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal change of circulating tumour cell count and its relation to prognosis in advanced intrahepatic cholangiocarcinoma patients.
Jiang S; Tang W; Huang B
Scand J Clin Lab Invest; 2023 Jul; 83(4):234-240. PubMed ID: 37199131
[TBL] [Abstract][Full Text] [Related]
3. Octamer-binding transcription factor 4-positive circulating tumor cell predicts worse treatment response and survival in advanced cholangiocarcinoma patients who receive immune checkpoint inhibitors treatment.
Pei F; Tao Z; Lu Q; Fang T; Peng S
World J Surg Oncol; 2024 Apr; 22(1):110. PubMed ID: 38664770
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
Sastre J; Maestro ML; Gómez-España A; Rivera F; Valladares M; Massuti B; Benavides M; Gallén M; Marcuello E; Abad A; Arrivi A; Fernández-Martos C; González E; Tabernero JM; Vidaurreta M; Aranda E; Díaz-Rubio E
Oncologist; 2012; 17(7):947-55. PubMed ID: 22643538
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Total, PTEN
Di Lorenzo G; Zappavigna S; Crocetto F; Giuliano M; Ribera D; Morra R; Scafuri L; Verde A; Bruzzese D; Iaccarino S; Costabile F; Onofrio L; Viggiani M; Palmieri A; De Placido P; Marretta AL; Pietroluongo E; Luce A; Abate M; Navaeiseddighi Z; Caputo VF; Celentano G; Longo N; Ferro M; Morelli F; Facchini G; Caraglia M; De Placido S; Buonerba C
Clin Genitourin Cancer; 2021 Oct; 19(5):e286-e298. PubMed ID: 33958297
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
[TBL] [Abstract][Full Text] [Related]
7. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients.
Gu T; Li J; Chen T; Zhu Q; Ding J
Int Urol Nephrol; 2023 Apr; 55(4):883-892. PubMed ID: 36709467
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
10. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
Bidard FC; Peeters DJ; Fehm T; Nolé F; Gisbert-Criado R; Mavroudis D; Grisanti S; Generali D; Garcia-Saenz JA; Stebbing J; Caldas C; Gazzaniga P; Manso L; Zamarchi R; de Lascoiti AF; De Mattos-Arruda L; Ignatiadis M; Lebofsky R; van Laere SJ; Meier-Stiegen F; Sandri MT; Vidal-Martinez J; Politaki E; Consoli F; Bottini A; Diaz-Rubio E; Krell J; Dawson SJ; Raimondi C; Rutten A; Janni W; Munzone E; Carañana V; Agelaki S; Almici C; Dirix L; Solomayer EF; Zorzino L; Johannes H; Reis-Filho JS; Pantel K; Pierga JY; Michiels S
Lancet Oncol; 2014 Apr; 15(4):406-14. PubMed ID: 24636208
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial.
Basso U; Facchinetti A; Rossi E; Maruzzo M; Conteduca V; Aieta M; Massari F; Fraccon AP; Mucciarini C; Sava T; Santoni M; Pegoraro C; Durante E; Nicodemo M; Perin A; Bearz A; Gatti C; Fiduccia P; Diminutto A; Barile C; De Giorgi U; Zamarchi R; Zagonel V
Oncologist; 2021 Sep; 26(9):740-750. PubMed ID: 34077597
[TBL] [Abstract][Full Text] [Related]
13. A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
Barbazán J; Muinelo-Romay L; Vieito M; Candamio S; Díaz-López A; Cano A; Gómez-Tato A; Casares de Cal Mde L; Abal M; López-López R
Int J Cancer; 2014 Dec; 135(11):2633-43. PubMed ID: 24752533
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study.
Bork U; Rahbari NN; Schölch S; Reissfelder C; Kahlert C; Büchler MW; Weitz J; Koch M
Br J Cancer; 2015 Apr; 112(8):1306-13. PubMed ID: 25867263
[TBL] [Abstract][Full Text] [Related]
17. Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer.
Sotelo MJ; Sastre J; Maestro ML; Veganzones S; Viéitez JM; Alonso V; Grávalos C; Escudero P; Vera R; Aranda E; García-Alfonso P; Gallego-Plazas J; Lopez C; Pericay C; Arrivi A; Vicente P; Ballesteros P; Elez E; López-Ladrón A; Díaz-Rubio E
Ann Oncol; 2015 Mar; 26(3):535-41. PubMed ID: 25515656
[TBL] [Abstract][Full Text] [Related]
18. High Epithelial Cell Adhesion Molecule-Positive Circulating Tumor Cell Count Predicts Poor Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization.
Shen J; Wang WS; Zhu XL; Ni CF
J Vasc Interv Radiol; 2018 Dec; 29(12):1678-1684. PubMed ID: 30392801
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors.
Castello A; Carbone FG; Rossi S; Monterisi S; Federico D; Toschi L; Lopci E
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32092983
[TBL] [Abstract][Full Text] [Related]
20. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
Zhou J; Dong F; Cui F; Xu R; Tang X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
